WEC
NBIX icon

Winslow Evans & Crocker’s Neurocrine Biosciences NBIX Stock Holding History

Winslow Evans & Crocker’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$5K Hold
55
– – ﹤0.01% 1092
2020
Q3 		$5K Hold
55
– – ﹤0.01% 884
2020
Q2 		$7K Sell
55
-1
-2% -$111 ﹤0.01% 809
2020
Q1 		$6K Hold
56
– – ﹤0.01% 823
2019
Q4 		$6K Buy
+56
New +$5.86K ﹤0.01% 939

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winslow Evans & Crocker's NBIX Position: Q4 2020 in Review

Winslow Evans & Crocker held its Neurocrine Biosciences (NBIX) position steady in Q4 2020 at 55 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

Winslow Evans & Crocker first reported a position in NBIX in Q4 2019 and has held it in 5 quarters since. The position peaked at $7K in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Winslow Evans & Crocker held 55 shares of Neurocrine Biosciences worth $5K as of Q4 2020.
  • Winslow Evans & Crocker left its Neurocrine Biosciences share count unchanged in Q4 2020.
  • Neurocrine Biosciences made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1092 holding.
  • Winslow Evans & Crocker first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 5 quarters since.
  • Winslow Evans & Crocker's Neurocrine Biosciences position peaked at $7K in Q2 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.